Opinion|Videos|June 19, 2024
PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access
In their closing remarks, the panel shares their view on the future of prescription digital therapeutics and the prospects for the widespread adoption and implementation of these therapeutics in health care systems.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How can payers work with providers to establish protocols for appropriate PDT prescribing and monitoring efficacy?
- What opportunities exist for collaborative demonstration projects across payers, providers, manufacturers, and other stakeholders to generate evidence on optimal implementation strategies?
- How might PDTs potentially help mitigate or reduce healthcare disparities and inequities in access to treatment or health outcomes across different populations?
- How important is it that Congress pass the Access to Prescription Digital Therapeutics Actas you consider the long-term value PDTs can have on improving care to patients?
Advertisement
Related to this article
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5